Skip to content

VisAR 2.73

by Novarad Corporation

VisAR 2.73 is a Class II device made by Novarad Corporation, cleared under FDA 510(k) K220146 on 27 May 2022 and listed in FDA GUDID since 16 Dec 2024 (UDI-DI B109VISAR2730), active as of 23 Oct 2026.

Active United States. Also listed in GUDID (US).

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 23 Oct 2026

Documents

510(k) K220146

FDA submission, from GUDID

Trust

Unverified

Source GUDID, synced 23 Oct 2026.

Regulatory status

as of registry sync 23 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing NumberB109VISAR2730 UDI-DI Date16 Dec 2024ListedStatusListed GUDID: in commercial distribution
United StatesFDA 510(k)SESE from GUDID Substantially Equivalent · Traditional NumberK220146 Date27 May 2022DecidedStatusActive

Official records

Across registries

2 registries list this device

  • FDA 510(k) K220146 decided 27 May 2022 Active
  • FDA GUDID UDI-DI B109VISAR2730 listed 16 Dec 2024 Listed

Timeline

2 dated events

  1. Cleared FDA 510(k) K220146
  2. Listed FDA GUDID B109VISAR2730

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

GUDID

Trade name
VisAR
Generic name
Surgical planning/navigation-enhancement system
Model / reference
VisAR 2.73
Primary DI / UDI-DI
B109VISAR2730
510(k) Number
FDA product code
OLO
GMDN term
Surgical planning/navigation-enhancement system
Device class
Class II
Regulation number
882.4560
GUDID distribution status
In Commercial Distribution

Similar devices in this category

Other devices filed under Surgical planning/navigation-enhancement system.

Other devices from Novarad Corporation

  • NovaPACS 9.1.5

    Class II
  • NovaPACS 9.1.6

    Class II
  • VisAR 3.0.67

    Class II
  • VisAR 3.1.36

    Class II

See all devices from Novarad Corporation →

Properties

  • Prescription use
  • Lot / batch number
Other properties (13, all answered No)